Human mesenchymal stem cells alter the gene profile of monocytes from patients with Type 2 diabetes and end-stage renal disease

Andrea F Wise, Timothy M Williams, Stephen A Rudd, Christine A Wells, Peter G Kerr, Sharon D Ricardo

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)


AIM: Macrophage infiltration contributes to the pathogenesis of Type 2 diabetes. Mesenchymal stem cells (MSCs) possess immunomodulatory properties, making them an ideal candidate for therapeutic intervention. This study investigated whether MSCs can modulate the phenotype of monocytes isolated from Type 2 diabetic patients with end-stage renal disease. MATERIALS METHODS: Monocytes from control (n = 4) and Type 2 diabetic patients with end-stage renal disease (n = 5) were assessed using flow cytometry and microarray profiling, following 48 h of co-culture with MSCs. RESULTS: Control subjects had a greater proportion of CD14++CD16- monocytes while diabetic patients had a higher proportion of CD14++CD16+ and CD14+CD16++ monocytes. MSCs promoted the proliferation of monocytes isolated from diabetic patients, reduced HLA-DR expression in both groups and promoted the expression of anti-inflammatory genes. CONCLUSION: MSC-derived factors alter the polarization of monocytes isolated from healthy and diabetic subjects toward an M2 phenotype.
Original languageEnglish
Pages (from-to)145-158
Number of pages14
JournalRegenerative Medicine
Issue number2
Publication statusPublished - 2 Mar 2016


  • end-stage renal disease
  • macrophages
  • mesenchymal stem cells
  • monocytes
  • Type 2 diabetes

Cite this